Thermo Fisher launches Biomarker Translational Center

A year ago, mass spectrometry experts Thermo Fisher Scientific ($TMO) helped launch a new Biomarker Research Center in Tokyo. Now, the company is doing the same thing a little closer to home, with the establishment of a new Biomarker Translational Center (BT Center) in Cambridge, MA. As it did in the Japanese center, Thermo Fisher will use the expertise it has garnered at BRIMS--its Biomarker Research Initiatives in Mass Spectrometry project. "Through the vertical integration with the unique talent in MS-based biomarker discovery and high-throughput quantitative assay development at BRIMS, we aim to expand our pipeline of new protein and peptide biomarkers with potential as clinical assays," Bruno Darbouret, director of research and development for Thermo Fisher, said in a statement. "Ultimately, this development effort will speed the commercialization of diagnostic tests that address life threatening diseases." More here

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.